Georgopoulos 2025 — HLA-modulated viral persistence in ME/CFS (B-Gen-1 cross-condition anchor)

One-paragraph summary

In-silico binding-affinity analysis of HLA alleles against >10,000 herpesvirus antigens, then extending to SARS-CoV-2 (Long COVID) and Borrelia burgdorferi (post-treatment Lyme disease syndrome / PTLDS). Two ME/CFS susceptibility alleles (HLA-C07:04 and HLA-DQB103:03) bind virus antigens significantly weaker than two protective alleles (HLA-B08:01 and HLA-DPB102:01; P < 0.001). The susceptibility alleles also bound SARS-CoV-2 glycoprotein and 5 Borrelia proteins weakly; the protective alleles bound them strongly. The framework: HLA susceptibility alleles fail to clear pathogen antigens → antigen persistence → chronic immune activation → ME/CFS / LC / PTLDS phenotype. This is the first cross-condition evidence partially closing B-Gen-1: the autoimmune-genetic-risk module (H5) operates not only via tolerance failure (CTLA4 / PTPN22) but via HLA-modulated pathogen-antigen escape. Predicts HLA-DQB1*03:03 (and other ME/CFS susceptibility alleles) should enrich in post-viral FM patients vs sporadic FM.

Claims as triples

• HLA_susceptibility_allele — modulates → pathogen_antigen_persistence [evidence: in silico binding affinity P<0.001; confidence: emerging]
• HLA_DQB1_03_03 — increases_risk → me_cfs [evidence: prior GWAS replication confirmed in this study; confidence: emerging]
• HLA_C_07_04 — increases_risk → me_cfs [evidence: prior GWAS replication confirmed in this study; confidence: emerging]
• HLA_B_08_01 — protects_against → me_cfs [evidence: in silico strong binding to HHV antigens; confidence: emerging]
• HLA_DPB1_02_01 — protects_against → me_cfs [evidence: in silico strong binding to HHV antigens; confidence: emerging]
• HLA_susceptibility_pattern — extends_to → post_covid_syndrome [evidence: same alleles weak-binding to SARS-CoV-2 glycoprotein; confidence: emerging]
• HLA_susceptibility_pattern — extends_to → post_treatment_lyme_disease_syndrome [evidence: same alleles weak-binding to 5 Borrelia proteins; confidence: emerging]
• pathogen_antigen_persistence — drives → me_cfs [evidence: framework consolidation; confidence: emerging]

Methods note

In silico approach using IEDB binding-affinity prediction across >10,000 herpesvirus antigens (9 HHV strains). HLA susceptibility/protection allele identification done in prior GWAS — this study tested the binding-affinity-modulation hypothesis. Cross-condition extension via the same allele-set binding to SARS-CoV-2 and Borrelia antigens. Replication is in silico, not patient-derived; no direct ME/CFS-cohort confirmation of weak-binding-protein persistence yet.

Limitations

• In silico binding affinity, not measured in patient samples
• Pathogen-antigen-persistence link inferred from binding affinity, not directly demonstrated
• The two ME/CFS susceptibility alleles tested are not the canonical celiac/T1DM HLA-DQ2/DQ8 — they're DQB103:03 and C07:04. FM-relevant question remains: do the H5 module HLA-DQ2/DQ8 carriers ALSO show this pattern in FM, or do the FM-relevant susceptibility alleles differ from the ME/CFS-relevant ones?
• The susceptibility/protective alleles for FM specifically are not yet identified in any GWAS at population level (Kerrebijn 2025 shows no immune-tissue heritability enrichment); FM HLA stratifiers must be derived from case-only PRS within FM-IgG-positive cohorts

Open questions raised

• Q-Gen-10 (new): Do FM-IgG-positive patients carry HLA-C07:04 / DQB103:03 (ME/CFS susceptibility) at population baseline, or enriched? Cross-condition HLA-cross-pattern test.
• Q-Gen-11 (new): Is HLA-modulated pathogen-antigen escape the upstream of B-Gen-1, parallel to celiac-HLA-DQ2/DQ8 gluten-peptide presentation? If yes, the H5 framework should be reframed as a general HLA-immune-escape-failure module with celiac and ME/CFS as two specific instances.
• Q-Gen-12 (new): Does an FM cohort genotyped for both the ME/CFS susceptibility alleles AND the celiac HLA-DQ2/DQ8 haplotypes show: (a) one allele set enriched, (b) both, (c) a third FM-specific allele pattern? Resolves whether H5 is "FM = ME/CFS HLA pattern + celiac barrier failure" or "FM has its own HLA architecture."

Triangulation notes

• Partially closes B-Gen-1 (Autoimmune-genetic risk module ↔ H1 FM subtype) via cross-condition transfer. The H5 framework's HLA-DQ2/DQ8 arm is anchored in celiac/T1DM literature; this paper supplies the parallel arm in ME/CFS literature. Both arms now have HLA-mediated immune-escape mechanisms.
• Reframes Kerrebijn 2025: the absence of HLA-immune-tissue heritability enrichment in the FM GWAS is consistent with FM being a mosaic of ME/CFS-style HLA susceptibility + celiac-style HLA susceptibility + other allele sets — washing out at population level but separable in subset analysis.
• Extends B1 bridge (Long COVID ↔ FM): same HLA susceptibility pattern operates in SARS-CoV-2 antigen binding, supporting the post-COVID FM = HLA-modulated viral persistence framing.
• Compatible with HERV reactivation framework (B7): HLA-mediated immune escape might also operate on HERV-W ENV antigens; testable extension.
• Maes group preeclampsia paper (Omar 2025, also accepted in this batch) shows soluble CTLA-4 in chronic fatigue — same authors' broader chronic-fatigue-immune-checkpoint framework; the two papers triangulate the H5 immune-tolerance-failure arm at two molecular levels (HLA + soluble checkpoint).

Bridges

• B-Gen-1 partial closure: this paper supplies cross-condition (ME/CFS) HLA-immune-escape mechanism evidence. Bridge advances from bridging → bridging-with-partial-evidence. Full closure requires the FM-direct HLA carriage frequency study (Q-Gen-1) or PRS analysis (Q-Gen-2).
• B1 extension: HLA-modulated pathogen persistence as candidate upstream of B1 (LC ↔ FM autoantibody chain).

Ontology additions needed

• Consider adding HLA_C_07_04, HLA_DQB1_03_03, HLA_B_08_01, HLA_DPB1_02_01 as new gene_variant entities
• Consider adding pathogen_antigen_persistence as new mechanism entity
• Consider adding post_treatment_lyme_disease_syndrome (PTLDS) as new comorbidity for cross-condition extension

Chain-map update

• H5 chain reframing candidate: the HLA-DQ2/DQ8 + celiac framing of H5 may be a subset of a broader "HLA-immune-escape-failure module" — celiac-spectrum HLA pattern is one instance; ME/CFS-pattern is another. FM may show either or both. Worth tracking as H5 v0.2 sub-framing.

Confidence-tier framing

• HLA-mediated pathogen-antigen binding affinity differential: emerging (in silico evidence, P<0.001)
• HLA-modulated immune escape as ME/CFS upstream: emerging
• Cross-condition extension to FM: inferred (predicted by framework; no FM-direct evidence yet)
• B-Gen-1 closure: partial (cross-condition evidence; FM-direct gate Q-Gen-1 still open)